APPROVAL: Pfizer Inc. says the Food and Drug Administration approved its rheumatoid arthritis drug Xeljanz, a twice-per-day pill.
WHO IT'S FOR: Xeljanz is designed to slow the progression of moderate to severe rheumatoid arthritis. It is approved for patients who either cannot take methotrexate, a standard treatment for the disease, or haven't been helped by it. Xeljanz interferes with enzymes that contribute to tissue inflammation.
THE BIG PICTURE: Rheumatoid arthritis is a major area of research for drug companies because it is a chronic condition, meaning patients will likely take the drugs regularly for a long time.
Mike Adams - Get Out of My Class and Leave America
Paging MSM: Future predicted by climate change fear-mongers has arrived
Arkansas Open Carrier Convicted - Bearing Arms - Arkansas, open carry
Small But Honest Columnist Again Forced to Correct Highest-Rated Show on Cable TV | Human Events
Republican Party, R.I.P. (1854 - 2016) | RedState
Obama’s NLRB just redefined the word “employer” and it’s going to be bad - Hot Air
John Ransom - Chinese Markets Bear Stamp: Made in USA